
Alveo and Royal GD Partner for Rapid Animal Diagnostics
Alveo Technologies and Royal GD have announced a long-term partnership to expand their joint offerings in rapid molecular diagnostics for animal health, announced in a press release. Their first co-developed product, the Alveo Sense™ Poultry Avian Influenza test, was introduced in the EU in late 2024 and is now expanding into the Middle East and Northern African markets.
The partnership aims to meet the growing demand for rapid, portable diagnostics by focusing on the co-development and distribution of products across multiple species, including poultry, cattle, swine, and equine. Royal GD will serve as a development and global distribution partner for the Alveo Sense Poultry Avian Influenza test, which has already been validated for the Middle East market.
The Alveo Sense test detects and differentiates between Avian Influenza Type A, H5, and H7 or H9 with over 99% specificity and 98.3% sensitivity for H5. It provides results in under 45 minutes using cloacal and oropharyngeal samples, with data uploaded to the cloud for real-time insights into viral outbreaks.
This partnership addresses critical needs in animal health by providing rapid diagnostics that eliminate lab bottlenecks and offer near real-time data to stakeholders, enhancing disease control measures and food supply safety.
We hope you enjoyed this article.
Consider subscribing to one of several newsletters we publish like Life AI Weekly.
Also, consider following us on social media:
More from: Healthcare & Life Sciences
ConcertAI Integrates ASCO Guidelines into AI Precision Suite
Transcripta Bio and Microsoft Research Collaborate on AI-Driven Gene Discovery
Skypoint Strengthens Leadership Team with Key Executive Appointments
Tevogen Bio Launches AI Initiative with Microsoft and Databricks
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read more